Hemostemix Inc. (HEM.V)

CAD 0.09

(-5.26%)

Gross Profit Summary of Hemostemix Inc.

  • Hemostemix Inc.'s latest annual gross profit in 2023 was -223.00 CAD , up 54.95% from previous year.
  • Hemostemix Inc.'s latest quarterly gross profit in 2024 Q2 was -25.00 CAD , down 0.0% from previous quarter.
  • Hemostemix Inc. reported a annual gross profit of -495.00 CAD in annual gross profit 2022, up 55.04% from previous year.
  • Hemostemix Inc. reported a annual gross profit of -1101.00 CAD in annual gross profit 2021, up 55.02% from previous year.
  • Hemostemix Inc. reported a quarterly gross profit of -25.00 CAD for 2024 Q1, up 55.36% from previous quarter.
  • Hemostemix Inc. reported a quarterly gross profit of -56.00 CAD for 2023 Q1, up 54.84% from previous quarter.

Annual Gross Profit Chart of Hemostemix Inc. (2023 - 2013)

Historical Annual Gross Profit of Hemostemix Inc. (2023 - 2013)

Year Gross Profit Gross Profit Growth
2023 -223.00 CAD 54.95%
2022 -495.00 CAD 55.04%
2021 -1101.00 CAD 55.02%
2020 -2448.00 CAD -45.02%
2019 -1688.00 CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%
2016 - CAD 100.0%
2015 -36.87 Thousand CAD 0.0%
2014 - CAD 0.0%
2013 - CAD 0.0%

Peer Gross Profit Comparison of Hemostemix Inc.

Name Gross Profit Gross Profit Difference
Arch Biopartners Inc. -128.99 Thousand CAD 99.827%
Covalon Technologies Ltd. 14.36 Million CAD 100.002%
Universal Ibogaine Inc. 1.07 Million CAD 100.021%
Kane Biotech Inc. 109.47 Thousand CAD 100.204%
MedMira Inc. -434.91 Thousand CAD 99.949%
Marvel Biosciences Corp. -887.51 Thousand CAD 99.975%
NervGen Pharma Corp. -145 Thousand CAD 99.846%
XORTX Therapeutics Inc. -188.54 Thousand CAD 99.882%